Yesterday, Amgen Inc. (AMGN) reported mixed top-line results from a phase III study evaluating Vectibix in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment for metastatic colorectal cancer (mCRC). The trial had two primary endpoints – progression-free and overall survival. Results showed that Vectibix, in combination with FOLFIRI, significantly improved progression-free survival (compared to [...] (AMGN) Mixed Results for Amgen’s Vectibix